Clinical overview of promising nonthienopyridine antiplatelet agents.
Three novel nonthienopyridine antiplatelet agents--cangrelor, ticagrelor (AZD6140), and SCH 530348--are in advanced clinical testing in patients with coronary artery disease. Cangrelor and ticagrelor are direct and reversible inhibitors of the platelet adenosine 5'-diphosphate P2Y12 receptor, whereas SCH 530348 is a thrombin receptor antagonist. Clinical data available to date for each of these compounds suggest that they have safety and efficacy profiles that will be advantageous to patients with acute coronary syndromes or undergoing percutaneous intervention. We review the clinical features of these new platelet inhibition therapies.
Angiolillo
Dominick J
DJ
Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL FL32209, USA. dominick.angiolillo@jax.ufl.edu
Guzman
Luis A
LA
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000249:Adenosine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000628:therapy; D004359:Drug Therapy, Combination; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D058919:Purinergic P2 Receptor Antagonists; D011725:Pyridines / Q000627:therapeutic use*; D018179:Receptors, Thrombin / Q000037:antagonists & inhibitors; D000077486:Ticagrelor
D007783:Lactones; D010975:Platelet Aggregation Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D011725:Pyridines; D018179:Receptors, Thrombin; D000249:Adenosine Monophosphate; C117446:cangrelor; D000077486:Ticagrelor; D000241:Adenosine; D001241:Aspirin; C530299:vorapaxar